<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976349</url>
  </required_header>
  <id_info>
    <org_study_id>254PD101</org_study_id>
    <secondary_id>2018-002995-42</secondary_id>
    <nct_id>NCT03976349</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease</brief_title>
  <acronym>REASON</acronym>
  <official_title>A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of single and
      multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with
      Parkinson's Disease (PD). The secondary objective of this study is to evaluate the
      pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified
      presence or absence of mutations in the leucine-rich repeated kinase 2 (LRRK2) gene, but also
      for patients without any verified PD-related genetic mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">January 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening (Day -42) up to Day 253</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; is a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of BIIB094</measure>
    <time_frame>Part A: pre-dose through Day 57, Part B: pre-dose through Day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Part A (SAD): BIIB094 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IT injection of BIIB094 during Part A [Single Ascending Dose (SAD)].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): BIIB094 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IT injection of BIIB094 during Part A (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): BIIB094 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IT injection of BIIB094 during Part A (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): BIIB094 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IT injection of BIIB094 during Part A (SAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): BIIB094 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IT injection of BIIB094 on multiple days during Part B [Multiple Ascending Dose (MAD)].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): BIIB094 (Non LRRK2) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants [Non leucine-rich repeat kinase 2 (Non LRRK2)] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): BIIB094 (LRRK2) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): BIIB094 (Non LRRK2) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): BIIB094 (LRRK2) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo during Part A [Single Ascending Dose (SAD)].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo on multiple days during Part B (MAD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB094</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part A (SAD): BIIB094 Dose 1</arm_group_label>
    <arm_group_label>Part A (SAD): BIIB094 Dose 2</arm_group_label>
    <arm_group_label>Part A (SAD): BIIB094 Dose 3</arm_group_label>
    <arm_group_label>Part A (SAD): BIIB094 Dose 4</arm_group_label>
    <arm_group_label>Part B (MAD): BIIB094 (LRRK2) Dose 2</arm_group_label>
    <arm_group_label>Part B (MAD): BIIB094 (LRRK2) Dose 3</arm_group_label>
    <arm_group_label>Part B (MAD): BIIB094 (Non LRRK2) Dose 2</arm_group_label>
    <arm_group_label>Part B (MAD): BIIB094 (Non LRRK2) Dose 3</arm_group_label>
    <arm_group_label>Part B (MAD): BIIB094 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part A (SAD): Matching Placebo</arm_group_label>
    <arm_group_label>Part B (MAD): Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use confidential health information in
             accordance with national and local participant privacy regulations.

          -  Diagnosed with PD in the last 7 years, without major motor fluctuations or dyskinesia
             that may interfere with study treatment and assessments in the opinion of the
             investigator after consultation with the Sponsor.

          -  Modified Hoehn and Yahr Stage ≤ 3.

        Key Exclusion Criteria:

          -  Montreal Cognitive Assessment (MoCA) score less than (&lt;) 23, dementia, or other
             significant cognitive impairment that, in the opinion of the Investigator, would
             interfere with study evaluation.

          -  History of any brain surgery for PD or a history of focused ultrasound treatment at
             any time; or history of neuromodulation procedures.

          -  Transient ischemic attack or stroke or any unexplained loss of consciousness within 1
             year before Screening.

          -  History of unstable angina, myocardial infarction, chronic heart failure, or
             clinically significant conduction abnormalities within 1 year before Screening.

          -  Poorly controlled diabetes mellitus, as defined by having dosage adjustment of
             diabetic medication within 3 months before dosing (Day 1) or glycosylated hemoglobin
             value greater than or equal to (≥) 8 percent (%) at Screening.

          -  History or positive test result at Screening for human immunodeficiency virus.

          -  History or positive test result at Screening for hepatitis C virus antibody.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Poon</last_name>
      <phone>312-503-8216</phone>
      <email>cynthia.poon@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee</last_name>
      <phone>248-957-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mule</last_name>
      <phone>216-444-1134</phone>
      <email>mulej@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Allen</last_name>
      <phone>503-494-9531</phone>
      <email>allenjea@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research NOCCR/VRG</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Hayzen, RN</last_name>
      <phone>865-305-9100</phone>
      <email>colleen.hayzen@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bixby</last_name>
      <phone>509-960-2818</phone>
      <email>mbixby@inwresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>QC H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma Khalil</last_name>
      <phone>514-398-2733</phone>
      <email>salma.khalil@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Migirov</last_name>
      <email>angelm@tlvmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jan.aasly@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laboratorios de Investigación Biocruces 3., Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Gomez Esteban</last_name>
      <phone>+34946006363</phone>
      <email>juancarlos.gomezesteban@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>Barcelona</city>
        <state>Vizcaya</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Balaguer Martinez</last_name>
      <phone>+3493 5656000</phone>
      <phone_ext>ext 1756</phone_ext>
      <email>ebalaguer@quironsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Santacruz</last_name>
      <phone>+34 93-2275785</phone>
      <email>trastornsmoviment@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Grandas</last_name>
      <phone>+34 91 5868339</phone>
      <email>francisco.grandas@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Square (Neurology) CRF Site Institute of Neurology &amp; the National Hospital for Neurology and Neurosurgery UCLH</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 0203 44 84531</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://foxtrialfinder.michaeljfox.org/trial/6358</url>
    <description>Fox Trial Finder</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

